Australia appears to be gain access to innovative treatment for obesity: Retatrutide. This dual agonist – acting on both GLP-1 and GIP receptors – has significant outcomes in international trials, suggesting considerable drops in weight. While availability hasn't occurred with TGA, several Australians dealing with weight-related health concerns